Technology
Health
Biotechnology

IMV

$3.71
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.11 (3.06%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell IMV and other stocks, options, ETFs, and crypto commission-free!

About

IMV Inc. Common Shares, also called IMV, is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. Read More The firm's patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.

Employees
Headquarters
Halifax, Nova Scotia
Founded
2000
Market Cap
161.93M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
11.65K
High Today
$3.91
Low Today
$3.68
Open Price
$3.80
Volume
7.85K
52 Week High
$7.21
52 Week Low
$3.60

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Cancer Prevention
Pharmaceutical
2018 IPO

News

Markets Insider22h

IMV Inc. to Present at Two Upcoming Investor Conferences

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that IMV Chief Executive Officer Frederic Ors will present at the Spring Investor Summit and the HC Wainwright Global Life Sciences Conference during April 2019. Details on each conference and presentation are as follows: • Venue: Spring Investor Summit, being held April 1-2, 2019 • Date of Presentation: Monday, April 1 • Time: 8:30 a.m. ET • Location: JW Marriott Hotel, Essex House, New York City • Venue: HC Wainw...

15
Seeking AlphaMar 22

IMV INC (IMMVD) CEO Fred Ors on Q4 2018 Results - Earnings Call Transcript

IMV INC (OTCQX:IMMVD) Q4 2018 Earnings Conference Call March 22, 2019 8:00 AM ET Company Participants Pierre Labbé - CFO Fred Ors - CEO Stephan Fiset - VP, Clinical Research Conference Call Participants David Novak - Raymond James Andre Uddin - Mackie Research Capital Endri Leno - National Bank Doug Loe - Echelon Wealth Partners Operator Good day, ladies and gentlemen, and welcome to the IMV 2018 Earnings Call. At this time, all lines are in a listen-only mode. Later we will conduct a question-an...

19
BusinessWireMar 21

IMV Inc. Announces 2018 Year-end Financial and Operational Results and Provides Updates on Key Clinical Programs

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today released its financial and operational results for year ending December 31, 2018. “IMV made significant advances in 2018,” said Frederic Ors, Chief Executive Officer. “Foundational changes, including shifting the name of the corporation to IMV and listing on Nasdaq, are enabling us to access to a larger pool of investors and allow us to better communicate our value proposition glob...

0
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.